BioAdaptives Inc. Introduces XcellaraHeart(TM): the World's First Stem Cell Mobilizer with a Targeted Cardiac Homing Signal

The flagship product of the new Xcellara™ cellular wellness platform is backed by a randomized, double-blind, placebo-controlled human clinical trial that showed an average increase of 268.8% in circulating stem cells after 4 weeks.

Raccontata damorningstar.com